Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sleep and CSF Amyloid-beta Modulation
NCT02063217Completed
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sodium oxybate in Alzheimer's disease (AD), sponsored by Washington University School of Medicine. Primary endpoint: Percent Increase From Mean Baseline of Cerebrospinal Fluid Amyloid Beta at 10 hours. Started Dec 2013; status: completed.
02
Drugs
sodium oxybate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02063217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063217.